Latest News

  • Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic Read More
  • Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Read More
  • Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Read More

Investors

Learn More

Working at Alkermes

Join Our Team